Safety of secukinumab in hepatitis B virus

descriptionPublicationkeyboard_double_arrow_right Article 16 Oct 2017 English Publisher:WileyJournal:Journal of the European Academy of Dermatology and Venereology, volume 32 (issn: 0926-9959, eissn: 1468-3083,

Copyright policy )

Authors: S.L. Bevans; T.T. Mayo; B.E. Elewski;

doi: 10.1111/jdv.14608

Safety of secukinumab in hepatitis B virus

- Summary
- Metrics

Abstract

The usage of TNF antagonists in patients with hepatitis B virus (HBV) can result in viral reactivation and potential liver failure. However, little is known about the risk of viral reactivation with the newer IL-17 antagonists. We report a patient with seropositive hepatitis B, ankylosing spondylitis, and disabling palmar plantar psoriasis treated successfully with secukinumab without liver complications. This article is protected by copyright. All rights reserved.

Related Organizations

Alabama Agricultural and Mechanical University
United States
University of Alabama at Birmingham
United States

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	16
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 10%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%